Who is sponsoring NCT03636386?

NCT03636386 is sponsored by Quiropraxia y Equilibrio.

What drugs are being tested in NCT03636386?

Interventions in NCT03636386: Percutaneous microelectrolysis, Ultrasound therapy.

What condition does NCT03636386 study?

NCT03636386 studies Myofascial Trigger Point Pain (MTrP).

Is NCT03636386 still recruiting?

NCT03636386 is currently completed. Last updated 18 April 2023.

Are results published for NCT03636386?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-04-18 · How we verify

NCT03636386: MEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Percutaneous Microelectrolysis on Myofascial Trigger Points Pain.

Completed NA Results posted Last updated 18 April 2023

What this trial tests

NA trial testing Percutaneous microelectrolysis in Myofascial Trigger Point Pain (MTrP) in 48 participants. Completed in 4 September 2019.

Timeline

23 May 2018

Primary endpoint
14 December 2018

4 September 2019

Quick facts

Lead sponsor	Quiropraxia y Equilibrio
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	48
Start date	23 May 2018
Primary completion	14 December 2018
Estimated completion	4 September 2019
Sites	1 location across Chile

Drugs / interventions tested

Percutaneous microelectrolysis
Ultrasound therapy

Conditions studied

Myofascial Trigger Point Pain (MTrP) — all drugs for Myofascial Trigger Point Pain (MTrP) →

Sponsor

Quiropraxia y Equilibrio

Who can join

18 and older, any sex, with Myofascial Trigger Point Pain (MTrP). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Pain Pressure Threshold (PPT) Primary · PPTpre1 (baseline), PPTpost1 (post baseline), PPT2 (Day 3), PPT3 (Day 7), assessed an average of 30 minutes at each session

Pain Intensity expressed in kilograms per square centimeter(kg/cm2) reported by participants when performing algometry test at sensitive point of upper trapezius muscle. PPT was valued in four occasions: PPT1 pre (baseline), PPT1 post, PPT 2 (at day 3) and PPT 3 (at day 7). PPT will be evaluated through the BASELINE® pressure algometer.

PPTpre1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	1.4	± 0.2
Control Group (Ultrasound Therapy)	1.4	± 0.2

PPTpost1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	1.6	± 0.2
Control Group (Ultrasound Therapy)	1.6	± 0.2

PPT2

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	1.7	± 0.1
Control Group (Ultrasound Therapy)	1.6	± 0.2

PPT3

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	1.9	± 0.3
Control Group (Ultrasound Therapy)	1.7	± 0.2

PPTdiff1-1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	0.2	± 0.2
Control Group (Ultrasound Therapy)	0.2	± 0.1

PPTdiff2-1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	0.4	± 0.2
Control Group (Ultrasound Therapy)	0.2	± 0.2

PPTdiff3-1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	0.5	± 0.4
Control Group (Ultrasound Therapy)	0.3	± 0.3

Pain Intensity (PI) Secondary · PIpre1 (baseline), PIpost1 (post baseline), PI2 (Day 3), PI3 (Day 7), assessed an average of 3 minutes at each session

Magnitude of pain expressed in millimeters (mm) referred by participants. PI was evaluated through visual analogue scale at moment of performing pressure algometry test in the sensitive point of upper trapezius muscle. PI was assessed with an analogous visual scale where the participant will mark the pain generated by the algometry on a scale of 1 to 100 millimeters. PI was valued in four occasions: PI1 pre (baseline), PI1 post, PI 2 (at day 3) and PI 3 (at day 7).

PIpre1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	32.1	± 13.6
Control Group (Ultrasound Therapy)	31.4	± 15.1

PIpost1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	24.6	± 12.7
Control Group (Ultrasound Therapy)	24.8	± 15.1

PI2

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	21.6	± 11.0
Control Group (Ultrasound Therapy)	23.8	± 14.0

PI3

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	18.1	± 9.9
Control Group (Ultrasound Therapy)	20.0	± 13.2

PIdiff1-1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	-7.5	± 8.4
Control Group (Ultrasound Therapy)	-6.6	± 8.6

PIdiff2-1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	-10.5	± 11.9
Control Group (Ultrasound Therapy)	-7.6	± 12.1

PIdiff3-1

Group	Value	95% CI
Percutaneous Microelectrolysis Group (MEP)	-14.0	± 12.3
Control Group (Ultrasound Therapy)	-11.5	± 13.1

Sponsor's own description

The aim of the design is to investigate the value of percutaneous microelectrolysis (MEP) as an analgesic technique in myofascial trigger points. This research seeks to evaluate influence of cathode polar effects on the reduction of painful pressure (PPT) threshold and pain intensity (PI) in the myofascial trigger points (MTrPs) of upper trapezius muscle. An assessment with algometry and visual analog scale (VAS) will be made before applying the intervention. The study will evaluate changes in PPT and PI in a group exposed to percutaneous microelectrolysis (MEP) aplication compared to control group. Both groups will be provided with a baseline treatment of therapeutic ultrasound. Treatment will include three evaluation sessions. Subsequently, researchers will proceed to compare PPT and PI obtained from algometry test and VAS in each groups, and between groups, before and after the intervention. Changes obtained between sessions will be compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myofascial Trigger Point Pain (MTrP)

Currently open trials in the same condition.

NCT04445545 — High Intensity Laser Therapy (HILT) on Myofascial Trigger Points. · NA · recruiting

Other Quiropraxia y Equilibrio trials

Trials by the same sponsor.

NCT07125404 — Low-Level Laser Auriculotherapy in the Treatment of Myogenic Temporomandibular Disorders and Anxiety · NA · not yet recruiting
NCT04445545 — High Intensity Laser Therapy (HILT) on Myofascial Trigger Points. · NA · recruiting
NCT04008602 — Effectiveness of Quick Icing (QI) Technique on Strenght of Jump. · NA · suspended
NCT06465524 — High-intensity Laser Therapy and Stretching Exercises for Chronic Non-specific Neck Pain: a Feasibility Study · NA · completed
NCT05689788 — High-intensity Laser Therapy for Neck Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03636386 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Quiropraxia y Equilibrio
Last refreshed: 18 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03636386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing